AustralieFrV1, Ncbi, Curation, bibRecord, 003D20

F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.

Identifieur interne : 003D20 ( Ncbi/Curation ); précédent : 003D19; suivant : 003D21

F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.

Auteurs : Julie M. Proudfoot [Australie] ; Anne E. Barden [Australie] ; Kevin D. Croft [Australie] ; Jean-Marie Galano [France] ; Thierry Durand [France] ; Valérie Bultel-Poncé [France] ; Martin Giera [Pays-Bas] ; Trevor A. Mori [Australie]

Source :

Free radical research [ 1029-2470 ] ; 2016.

RBID : pubmed:27750456

Descripteurs français

KwdFr :
- Cholestérol HDL (métabolisme), Femelle, Humains, Isoprosane (métabolisme), Lipoprotéines LDL (métabolisme), Mâle, Phospholipides (métabolisme), Spectrométrie de masse ().
MESH :
- métabolisme : Cholestérol HDL, Isoprosane, Lipoprotéines LDL, Phospholipides.
- Femelle, Humains, Mâle, Spectrométrie de masse.

English descriptors

KwdEn :
- Cholesterol, HDL (metabolism), Female, Humans, Isoprostanes (metabolism), Lipoproteins, LDL (metabolism), Male, Mass Spectrometry (methods), Phospholipids (metabolism).
MESH :
- chemical , metabolism : Cholesterol, HDL, Isoprostanes, Lipoproteins, LDL, Phospholipids.
- methods : Mass Spectrometry.
- Female, Humans, Male.

Abstract

Low HDL cholesterol (HDL-C) is a risk factor for coronary artery disease (CAD). However, interventions that raise HDL-C have failed to reduce cardiovascular events. We previously reported that HDL is the main carrier of plasma F2-isoprostanes (F2-IsoPs) that are markers of oxidative stress formed upon oxidation of arachidonic acid. F2-IsoPs are predominantly associated with phospholipids. However, there is evidence that F2-IsoPs in the liver of rats treated with carbon tetrachloride associate with the neutral lipids. To date it is not known whether F2-IsoPs are found in the neutral lipids in HDL in humans. Possible candidate neutral lipids include cholesteryl esters, triglycerides, diglycerides, and monoglycerides. This study aimed to identify the lipid classes within native and oxidized HDL that contain F2-IsoPs. We showed that F2-IsoPs in HDL are bound to neutral lipids as well as phospholipids. HDL-3 contained the highest concentration of F2-IsoPs in all lipid classes before and after in vitro oxidation. Using targeted LC/MS and high resolution MS, we were unable to provide conclusive evidence for the presence of the synthesized standards 15(R)-15-F2t-isoP cholesterol and 1-ent-15(RS)-15-F2t-isoprostanoyl-sn-glycerol in the neutral lipids of HDL. Our findings show that oxidized lipids such as F2-IsoPs are found in the core and surface of HDL. However, the exact molecular species remain to be definitively characterized. Future studies are required to determine whether the presence of F2-IsoPs in neutral lipids alters HDL function.

DOI: 10.1080/10715762.2016.1250262
PubMed: 27750456

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001525
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001503
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001503
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003D20

Links to Exploration step

pubmed:27750456

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.</title>
<author><name sortKey="Proudfoot, Julie M" sort="Proudfoot, Julie M" uniqKey="Proudfoot J" first="Julie M" last="Proudfoot">Julie M. Proudfoot</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barden, Anne E" sort="Barden, Anne E" uniqKey="Barden A" first="Anne E" last="Barden">Anne E. Barden</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Croft, Kevin D" sort="Croft, Kevin D" uniqKey="Croft K" first="Kevin D" last="Croft">Kevin D. Croft</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galano, Jean Marie" sort="Galano, Jean Marie" uniqKey="Galano J" first="Jean-Marie" last="Galano">Jean-Marie Galano</name>
<affiliation wicri:level="1"><nlm:affiliation>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Durand, Thierry" sort="Durand, Thierry" uniqKey="Durand T" first="Thierry" last="Durand">Thierry Durand</name>
<affiliation wicri:level="1"><nlm:affiliation>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bultel Ponce, Valerie" sort="Bultel Ponce, Valerie" uniqKey="Bultel Ponce V" first="Valérie" last="Bultel-Poncé">Valérie Bultel-Poncé</name>
<affiliation wicri:level="1"><nlm:affiliation>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giera, Martin" sort="Giera, Martin" uniqKey="Giera M" first="Martin" last="Giera">Martin Giera</name>
<affiliation wicri:level="1"><nlm:affiliation>c Center for Proteomics and Metabolomics Leiden University Medical Center , Leiden , The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>c Center for Proteomics and Metabolomics Leiden University Medical Center , Leiden </wicri:regionArea>
<wicri:noRegion>Leiden </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mori, Trevor A" sort="Mori, Trevor A" uniqKey="Mori T" first="Trevor A" last="Mori">Trevor A. Mori</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27750456</idno>
<idno type="pmid">27750456</idno>
<idno type="doi">10.1080/10715762.2016.1250262</idno>
<idno type="wicri:Area/PubMed/Corpus">001525</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001525</idno>
<idno type="wicri:Area/PubMed/Curation">001503</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001503</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001503</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001503</idno>
<idno type="wicri:Area/Ncbi/Merge">003D20</idno>
<idno type="wicri:Area/Ncbi/Curation">003D20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.</title>
<author><name sortKey="Proudfoot, Julie M" sort="Proudfoot, Julie M" uniqKey="Proudfoot J" first="Julie M" last="Proudfoot">Julie M. Proudfoot</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barden, Anne E" sort="Barden, Anne E" uniqKey="Barden A" first="Anne E" last="Barden">Anne E. Barden</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Croft, Kevin D" sort="Croft, Kevin D" uniqKey="Croft K" first="Kevin D" last="Croft">Kevin D. Croft</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Galano, Jean Marie" sort="Galano, Jean Marie" uniqKey="Galano J" first="Jean-Marie" last="Galano">Jean-Marie Galano</name>
<affiliation wicri:level="1"><nlm:affiliation>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Durand, Thierry" sort="Durand, Thierry" uniqKey="Durand T" first="Thierry" last="Durand">Thierry Durand</name>
<affiliation wicri:level="1"><nlm:affiliation>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bultel Ponce, Valerie" sort="Bultel Ponce, Valerie" uniqKey="Bultel Ponce V" first="Valérie" last="Bultel-Poncé">Valérie Bultel-Poncé</name>
<affiliation wicri:level="1"><nlm:affiliation>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier , France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>b Institut des Biomolécules Max Mousseron (IBMM) UMR 5247, CNRS, Université de Montpellier, ENSCM , Montpellier </wicri:regionArea>
<wicri:noRegion>Montpellier </wicri:noRegion>
<wicri:noRegion>Montpellier </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Giera, Martin" sort="Giera, Martin" uniqKey="Giera M" first="Martin" last="Giera">Martin Giera</name>
<affiliation wicri:level="1"><nlm:affiliation>c Center for Proteomics and Metabolomics Leiden University Medical Center , Leiden , The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>c Center for Proteomics and Metabolomics Leiden University Medical Center , Leiden </wicri:regionArea>
<wicri:noRegion>Leiden </wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mori, Trevor A" sort="Mori, Trevor A" uniqKey="Mori T" first="Trevor A" last="Mori">Trevor A. Mori</name>
<affiliation wicri:level="1"><nlm:affiliation>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth , Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>a School of Medicine and Pharmacology , University of Western Australia, Royal Perth Hospital Unit , Perth </wicri:regionArea>
<wicri:noRegion>Perth </wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Free radical research</title>
<idno type="eISSN">1029-2470</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cholesterol, HDL (metabolism)</term>
<term>Female</term>
<term>Humans</term>
<term>Isoprostanes (metabolism)</term>
<term>Lipoproteins, LDL (metabolism)</term>
<term>Male</term>
<term>Mass Spectrometry (methods)</term>
<term>Phospholipids (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Cholestérol HDL (métabolisme)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Isoprosane (métabolisme)</term>
<term>Lipoprotéines LDL (métabolisme)</term>
<term>Mâle</term>
<term>Phospholipides (métabolisme)</term>
<term>Spectrométrie de masse ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cholesterol, HDL</term>
<term>Isoprostanes</term>
<term>Lipoproteins, LDL</term>
<term>Phospholipids</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mass Spectrometry</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cholestérol HDL</term>
<term>Isoprosane</term>
<term>Lipoprotéines LDL</term>
<term>Phospholipides</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Spectrométrie de masse</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Low HDL cholesterol (HDL-C) is a risk factor for coronary artery disease (CAD). However, interventions that raise HDL-C have failed to reduce cardiovascular events. We previously reported that HDL is the main carrier of plasma F2-isoprostanes (F2-IsoPs) that are markers of oxidative stress formed upon oxidation of arachidonic acid. F2-IsoPs are predominantly associated with phospholipids. However, there is evidence that F2-IsoPs in the liver of rats treated with carbon tetrachloride associate with the neutral lipids. To date it is not known whether F2-IsoPs are found in the neutral lipids in HDL in humans. Possible candidate neutral lipids include cholesteryl esters, triglycerides, diglycerides, and monoglycerides. This study aimed to identify the lipid classes within native and oxidized HDL that contain F2-IsoPs. We showed that F2-IsoPs in HDL are bound to neutral lipids as well as phospholipids. HDL-3 contained the highest concentration of F2-IsoPs in all lipid classes before and after in vitro oxidation. Using targeted LC/MS and high resolution MS, we were unable to provide conclusive evidence for the presence of the synthesized standards 15(R)-15-F2t-isoP cholesterol and 1-ent-15(RS)-15-F2t-isoprostanoyl-sn-glycerol in the neutral lipids of HDL. Our findings show that oxidized lipids such as F2-IsoPs are found in the core and surface of HDL. However, the exact molecular species remain to be definitively characterized. Future studies are required to determine whether the presence of F2-IsoPs in neutral lipids alters HDL function.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D20 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 003D20 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27750456
   |texte=   F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:27750456" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.

F2-Isoprostanes in HDL are bound to neutral lipids and phospholipids.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki